Roche Targets Weight-Loss Drug Market Dominated by Novo Nordisk, Eli Lilly
Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly.
Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly.
Goldman Sachs moved down its S&P 500 year-end target as a recent drawdown in the benchmark index amid a weakening growth outlook have impacted stocks' upside in 2025.
PepsiCo downgraded, HubSpot upgraded: Wall Street's top analyst calls
Business automation software provider Upland Software (NASDAQ: UPLD) met Wall Street’s revenue expectations in Q4 CY2024, but sales fell by 5.8% year on year to $68.03 million. On the other hand, next quarter’s revenue guidance of $62 million was less impressive, coming in 7.7% below analysts’ estimates. Its non-GAAP profit of $0.41 per share was significantly above analysts’ consensus estimates.
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the education services industry, including Lincoln Educational (NASDAQ:LINC) and its peers.
Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market value, a lesson ingrained in investors who lost money in tech stocks during 2022.
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale advantages of their larger peers.
Stocks under $10 pique our interest because they have room to grow (as well as the most affordable option contract premiums). That doesn’t mean they’re bargains though, and we urge investors to be careful as many have risky business models.
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.
Stocks trading in the $1-10 range are generally smaller players with less risk than their penny stock counterparts. But that doesn’t mean the underlying businesses are cheap, and we advise caution as many have questionable fundamentals.